SAN DIEGO, May 31, 2017 (GLOBE NEWSWIRE) -- Today marks the World Health Organization’s World No Tobacco Day, which aims to build awareness of the broader economic, environmental and health impacts of tobacco growing, manufacture and consumption. Next Generation Labs’ TFN Nicotine® is the only test-verified, non-tobacco derived, synthetic nicotine offering for the vape and pharmaceutical markets.
Most pharmaceutical and vape products use nicotine that is solely derived from tobacco, which until recently was the only commercially viable bulk source. Synthetic nicotine has now been scaled to larger production levels, and because it is molecularly identical to tobacco-derived nicotine and is manufactured under laboratory conditions, it is a better solution for consumers and industry players concerned about the environmental consequences of using tobacco-based nicotine ingredients. Significantly, products that use TFN Nicotine benefit from virtually odorless and tasteless nicotine, which helps create intrinsically more acceptable products for adult consumers, without compromising on nicotine satisfaction.
Vincent Schuman, Next Generation Labs CEO, comments: “The pharmaceutical and vape industries have fought for years to break their association with tobacco products and the issues that extend from tobacco growing and production. Now, thanks to the opportunities provided by synthetic nicotine, any manufacturer that uses nicotine as a vital ingredient can finally develop products that are unequivocally disassociated from tobacco. As a result we’ve seen demand for synthetic nicotine surge in the last year.”
This demand comes directly from consumers who want vaping products that are truly free from tobacco, and from e-liquid manufacturers who are able to introduce e-juices that likely do not fall under the FDA Tobacco Deeming Rule. Brands such as Lost Arts, NKTR, Digable, Enfuse, Mag7, PEEL, Sour Dream, Krumble, Technico, Defiant, Quantum, Dre-Lago and SUA have experienced tremendous success with their TFN e-liquid lines, creating some of the most vibrant taste profiles on the market thanks to the clean attributes of TFN Nicotine.
Interest has also increased from pharmaceutical companies who are seeking to phase out their reliance on tobacco-derived nicotine as an ingredient in their nicotine replacement and new drug development products.
Next Generation Labs sells TFN Nicotine directly to e-liquid and pharmaceutical manufacturers; to purchase TFN Nicotine please contact Vincent Schuman directly at Vincent@nextgenerationlabs.com.
About Next Generation Labs
Founded in 2014, Next Generation Labs developed TFN Nicotine®, the world’s leading synthetic nicotine that is not derived from tobacco. TFN Nicotine is used in over 40 e-liquid brands in the US and is playing a central role in helping revolutionize the pharmaceutical and vaping industries.
www.nextgenerationlabs.com